<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812954</url>
  </required_header>
  <id_info>
    <org_study_id>PSO-GOE</org_study_id>
    <secondary_id>50310</secondary_id>
    <nct_id>NCT01812954</nct_id>
  </id_info>
  <brief_title>Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jochen Schmitt.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is health economic analysis of medicinal treatment options for moderate-to-severe
      psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes
      will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for
      moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various
      different sources, including summary of product characteristics (SPCs) and the German S3
      guideline on psoriasis care, health care utilization data and official statistics.

      The study aims to investigate the comparative cost-effectiveness of biologic and conventional
      systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe
      plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled
      (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as
      well as indirect cost will be considered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cost per quality-adjusted life year (QALY) gained through treatment with each individual agent compared to supportive care as well as compared to placebo</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporins</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fumaric acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with moderate-to-severe psoriasis, who require systemic treatment to adequately
        control the disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -diagnosis of moderate-to-severe psoriasis

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Schmitt, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Dresden</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Jochen Schmitt.</investigator_full_name>
    <investigator_title>Director of Center for evidence-based healthcare</investigator_title>
  </responsible_party>
  <keyword>moderate-to-severe psoriasis</keyword>
  <keyword>cost utility analysis</keyword>
  <keyword>cost effectiveness analysis</keyword>
  <keyword>systemic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Acitretin</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

